KR101671361B1 - Pharmaceutical composition for preventing or treating hair loss comprising TYMP(thymidine phosphorylase) protein - Google Patents

Abstract

The present invention relates to a composition for preventing, treating or improving hair loss and promoting hair growth, comprising thymidine phosphorylase (TYMP) protein as an active ingredient. The composition for preventing hair loss or promoting hair growth comprising the TYMP protein according to the present invention as an active ingredient has no side effects when treating hair loss and can be used as drugs having an excellent hair growth effect in a short time and can be helpfully used in quasi drugs, cosmetics and health functional foods.

Description

[0001] The present invention relates to a pharmaceutical composition for prevention or treatment of hair loss comprising TYMP (thymidine phosphorylase) protein as an active ingredient,

The present invention relates to a composition for preventing, treating or improving hair loss comprising a TYMP protein as an active ingredient, and a composition for promoting hair growth or hair growth.

Hair loss refers to a state in which there is no hair on the area where the hair normally exists, and generally means that the hair of the scalp (coarse black hair) is removed. The Virgin Mary can cause cosmetic problems when she is out of color and has a different thickness. It is normal for Koreans with low hair density to have about 50-70,000 hairs and about 50-70 hairs per day to be missing. Therefore, if the number of hair that falls out when you sleep or close your hair exceeds 100, hair loss may be ongoing.

The causes of hair loss are diverse. The genetic cause and male hormone, androgen, are thought to be important factors in the occurrence of baldness, and it is presumed that some of them occur in the same path as male pattern hair loss, There are differences in aspects. Alopecia areata is thought to be an autoimmune disease. Alopecia are caused by temporary hair loss caused by severe physical and mental stress such as endocrine diseases, malnutrition, drug use, childbirth, fever, and surgery, and part of the hair does not fill the growth period and falls into the dormant state.

Among the symptoms of such hair loss, male hair loss is a hair loss in a person who has a family history of baldness in the twenties or thirties, and hair loss progresses gradually. The boundary between forehead and head is pushed backward, and the forehead spreads in M-shape on both sides of the temporal region, and hair loss gradually progresses to the parietal region of the head. The hair loss on the forehead is maintained on the forehead as compared with that of the male hair loss, and the hair in the center of the hair is tapered and the hair thinning is reduced. Also, it is rare for feminine hair loss to be completely bald because the degree of hair loss is weak and the forehead peeled off like male hair loss hair loss. In addition, alopecia areata is characterized by the appearance of circular or elliptical depilatory discs of various sizes (hair appears to disappear). It occurs primarily in the head, and rarely occurs in beard, eyebrows and eyelashes, and a large depilation may occur as the symptomatic area enlarges. If the entire hair is lost, it is classified as all-hair alopecia (frontal hair alopecia) and when the whole hair is lost, it is called generalized alopecia. In addition, resting hair alopecia begins 2 ~ 4 months after the onset of the cause of hair loss, hair thinning as a whole is reduced, and if the cause of irritation is removed, resting hair is restored to normal over several months.

As a conventional treatment method for such hair loss, in the case of male or female hair loss, a medicine to be applied such as minoxidil, a medicine to eat such as pinasteride, a hair transplantation and the like are used. In addition, topical steroids, systemic steroids, and immunotherapy are used to treat alopecia universalis. It is important to identify the cause of hair loss and to treat it because the hair is recovered when the cause is removed. However, when treating hair loss by such a conventional method, there is a problem of side effects because it relies on a drug therapy or a steroid preparation, and there is a problem that the speed of treatment is not fast and it is long. In addition, treatment with drugs or hair transplantation has a problem that the treatment cost is greatly increased. Minoxidil and finasteride are representative drugs used to promote hair growth. Minoxidil in the United States can cause side effects such as edema, arrhythmia and hairiness on unwanted areas, and the effects of minoxidil are most effective in 6 months to 1 year after use, The effect is known to be reduced. In addition, finasteride, developed by Merck, is known to inhibit the activity of 5-α-reductase, an enzyme that acts on the male hormone testosterone metabolism in hair follicles, but sexual dysfunction and depression Increased suicidal ideation has been reported. In addition, since it increases the possibility of birth defects, it is not applicable to women in fertility or women during pregnancy. In addition, it is known that if both drugs are discontinued, hair loss will proceed again. In addition, there are valproic acid, but it is known that the child's ability to develop cognition is greatly reduced when taking it during pregnancy. Thus, various conventional hair growth promoting methods have generally been attempted to promote hair growth with the aim of promoting blood circulation and nourishment of hair follicles, but the toxicity and side effects are also severe and the effect thereof is insufficient at present .

Accordingly, the present inventors have made intensive efforts to develop a substance capable of preventing hair loss and promoting hair growth without side effects, and as a result, they have confirmed that TYMP protein present in the body has an effect of promoting hair growth and completed the present invention.

It is an object of the present invention to provide a pharmaceutical composition for preventing or treating hair loss comprising TYMP protein as an active ingredient.

Another object of the present invention is to provide a quasi-drug composition, cosmetic composition and food composition for prevention or improvement of hair loss comprising TYMP protein as an active ingredient.

It is still another object of the present invention to provide a pharmaceutical composition, a quasi-drug composition, a cosmetic composition and a food composition for promoting hair growth or hair growth comprising TYMP protein as an active ingredient.

In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating hair loss comprising TYMP protein as an active ingredient.

In addition, the present invention provides a quasi-drug composition for prevention or improvement of hair loss comprising TYMP protein as an active ingredient.

The present invention also provides a cosmetic composition for preventing or improving hair loss comprising TYMP protein as an active ingredient.

In addition, the present invention provides a food composition for prevention or alleviation of hair loss comprising TYMP protein as an active ingredient.

The present invention also provides a pharmaceutical composition for promoting hair growth or hair growth comprising TYMP protein as an active ingredient.

In addition, the present invention provides a quasi-drug composition for promoting hair growth or hair growth comprising TYMP protein as an active ingredient.

The present invention also provides a cosmetic composition for promoting hair growth or hair growth comprising TYMP protein as an active ingredient.

The present invention also provides a food composition for promoting hair growth or hair growth comprising TYMP protein as an active ingredient.

The composition for promoting hair loss prevention or hair growth comprising the TYMP protein according to the present invention as an active ingredient has no side effects at the time of hair loss treatment and is excellent in hair growth effect in a short time so that it can be used as a pharmaceutical product and also can be used in quasi drugs, Can be usefully used.

FIG. 1 is a graph showing the results of measurement of cell proliferation for 40 hours after treatment of TYMP protein with DPC. FIG.
FIG. 2 is a back view of a mouse after 15 days of subcutaneous injection of TYMP protein after hair removal using C3H / HeN mouse hair removal agent.
FIG. 3 is a graph showing the results of measurement of increased hair growth weight (mg) of mouse after 15 days of subcutaneous injection of TYMP protein after hair removal using hair removal agent of C3H / HeN mouse.

Hereinafter, the present invention will be described in detail.

The present invention provides a pharmaceutical composition for preventing or treating hair loss and promoting hair growth or hair growth comprising TYMP protein as an active ingredient.

TYMP (thymidine phosphorylase) is an enzyme that reversibly converts thymidine to thymine and 2-deoxyribose-1-phosphate, and is known to be involved in DNA synthesis. In addition, the high expression of TYMP was confirmed in various solid tumors, mainly gastric cancer and colorectal cancer, and there was a positive correlation between angiogenesis, invasion, metastasis, and the like, and expression of TYMP was one of the prognostic factors (Cancer Sci. 2004 Nov; 95 (11): 851-7, Int. J. Clin. Oncol. 2006 Aug; 11 (4): 297-302). In other cases, inflammation has been reported in patients with glomerulonephritis, interstitial cystitis, chronic articular rheumatism, and inflammatory bowel disease (Nephron Clin Pract 2006; 102 (3) 4: c133-42, J. Urol. 2002 Jan; 167 (1): 347-51, Clin. Chim. Acta. 1993 Sep. 217 (1): 1-4, J. Gastroenterol. 3): 229-37). However, it has not been reported that TYMP is associated with hair loss symptoms and hair growth effect.

The TYMP protein may be composed of whole or part of a peptide having the effect of preventing or treating hair loss, promoting hair growth or hair growth, preferably comprising the amino acid sequence of SEQ ID NO: 1, and functional equivalents and variants .

The functional equivalents of the proteins include proteins and polypeptides that do not totally alter the activity of the protein molecule, and proteins that can function in the same manner are included within the scope of the present invention. The mutant is, for example, one obtained by deletion, substitution or addition of one or several amino acids in the amino acid sequence, 95% or more, preferably 98% or more, and more preferably 99% or more identity with the amino acid sequence And so on. The term "identity" is used herein to mean that, when a gap is introduced into two amino acid sequences or aligned (aligned) so as to have the highest degree of agreement without introducing a gap, the number of amino acid residues in the other amino acid sequence (%) Of the same number of amino acid residues in the amino acid sequence of SEQ ID NO. Refers to an integer of 2 to 10, for example, an integer of 2 to 7, 2 to 5, 2 to 4, and 2 to 3. Specific examples of natural variants include variants based on polymorphisms such as SNP (single base polymorphism), splice variants, and the like. The substitution is preferably a conservative amino acid substitution. And conservative amino acid substitution can have a structure or properties substantially equivalent to those of the human TYMP having the amino acid sequence. Conservative amino acids are amino acids other than nonpolar amino acids (glycine, alanine, phenylalanine, valine, leucine, isoleucine, methionine, proline and tryptophan) and polar amino acids (nonpolar amino acids), charged amino acids (acidic amino acids such as aspartic acid and glutamic acid) (Phenylalanine, tryptophan, tyrosine), branched amino acids (leucine, isoleucine, valine), and aliphatic amino acids (glycine, alanine, leucine), amino acids (arginine, histidine, lysine) and uncharged amino acids (amino acids other than charged amino acids) , Isoleucine, valine) and the like are known. In addition, the protein may include a protein having increased structural stability or increased protein activity due to mutation or modification of the amino acid sequence, such as heat, pH and the like.

The gene encoding the TYMP protein may be composed of the nucleotide sequence of SEQ ID NO: 2, and variants capable of functionally equivalent to the nucleotide are included in the scope of the present invention.

As a result of the addition, substitution or deletion of a base, the mutant capable of functionally performing the same function is at least 70% or more, preferably 80% or more, more preferably 90% or more 2, more preferably at least 95%, and is capable of encoding a protein exhibiting substantially the same physiological activity as the protein encoded by the nucleotide sequence shown in SEQ ID NO: 2. For example, although some base sequences have been modified by deletion, substitution, or insertion, they include variants that can function in a functionally equivalent manner to the nucleic acid molecule encoding the TYMP protein .

As used herein, the term " hair loss ", as used herein, is intended to include without limitation any male hair loss, female hair loss, round hair loss and resting hair loss, May be considered to be hair loss treated or prevented by the composition according to the present invention. Also, the composition according to the present invention has an excellent effect of preventing hair loss before hair loss starts.

As used herein, the term " hair growth " refers to hair growth, and " hair growth " refers to hair growth. The effect of the composition according to the present invention also includes the effect of promoting hair growth or hair growth.

As used herein, the term "prophylactic" means any action that inhibits or delays hair loss by administration of the composition of the present invention, and "treatment" means that the composition of the present invention alleviates or alleviates It means all acts.

The pharmaceutical compositions of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions. The pharmaceutical composition according to the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories, Can be used. Suitable formulations known in the art are preferably those disclosed in Remington ' s Pharmaceutical Sciences, Mack Publishing Company, Easton PA.

Examples of carriers, excipients and diluents that can be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

When the pharmaceutical composition according to the present invention is formulated, it is prepared using diluents or excipients such as fillers, extenders, binders, humectants, disintegrants, surfactants and the like which are usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, lactose, gelatin, . In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the non-aqueous solvent and suspension include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

The composition of the present invention may be administered in a pharmaceutically effective amount.

The term "pharmaceutically effective amount" as used herein means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level will vary depending on the species and severity, age, sex, The type of drug, the activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and the rate of release, the duration of the treatment, factors including co-administered drugs, and other factors well known in the medical arts. The composition of the present invention may be administered as an individual therapeutic agent or in combination with another therapeutic agent, and may be administered sequentially or simultaneously with a conventional therapeutic agent. And can be administered singly or multiply. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without adverse effect, and can be easily determined by those skilled in the art. The preferred dosage of the composition of the present invention will depend on the condition and the weight of the patient, the degree of disease, the type of drug, the route of administration and the period of time, and the appropriate total daily dose may be determined by treatment, Generally, an amount of 0.001 to 1000 mg / kg, preferably 0.05 to 200 mg / kg, more preferably 0.1 to 100 mg / kg, can be administered in a single dose, divided into several times a day. Any object can be applied as long as it is an object for prevention or treatment of hair loss, without any particular limitation. For example, it can be applied to any individual such as a monkey, a dog, a cat, a rabbit, a guinea pig, a rat, a mouse, a cattle, a pig, a goat, Including without limitation. For example, transdermal administration through topical application may be used, but is not limited thereto.

Meanwhile, the method of administering the pharmaceutical composition according to the present invention is not particularly limited, and it can be administered orally or in a form applied to the hair loss region or applied to a region where the progress of hair loss is predicted. In addition, there is no particular limitation on the method of administration, and it is also possible to inject directly into the site where the progress of hair loss or hair loss is predicted. In addition, there is no particular limitation on the method of administration, and it is possible to inject by injecting into the artery or vein.

Also, the dosage level selected from the composition will depend upon the activity of the active ingredient, the route of administration, the severity of the hair loss to be treated, and the condition and previous history of the hair loss to be treated. It is, however, within the knowledge of the art to gradually increase the dose until the desired effect is achieved, starting with a dose of the active ingredient at a level lower than that required to achieve the desired therapeutic effect, Sex, body shape, and body weight. The composition may be further processed before being formulated into a pharmaceutically acceptable pharmaceutical formulation and may be preferably ground or ground into smaller particles. Also, the composition will vary depending on the condition and the patient being treated, but it can be determined non-ingeniously.

The compositions of the present invention may be formulated for administration by methods such as direct application or dispensing to the skin, e.g., the hair or scalp, such as, for example, creams, lotions, ointments, aerosols, shampoos, gels, Lt; / RTI > Methods for formulation ingredients and formulations suitable for each formulation are well known in the art. Those skilled in the art can appropriately select and use various formulation ingredients used in the preparation of these external preparations when manufacturing these preparations.

The hair to which the composition of the present invention is applied includes hair follicles and hair follicles, hair and eyelashes and eyelashes, beard, armpits, pubic hair, hair follicles and hair follicles.

Further, the present invention provides a quasi-drug composition for preventing or improving hair loss and promoting hair growth or hair growth comprising TYMP protein as an active ingredient.

The term "quasi-drug" in the present invention means a fiber, a rubber product or the like used for the purpose of treating, alleviating, treating or preventing a disease of a human or an animal, a weak action on the human body, Or products similar to those which are not machinery, preparations used for sterilization, insecticides and similar uses for the prevention of infections, for the purpose of diagnosis, treatment, alleviation, treatment or prevention of diseases of human beings or animals Machinery, or apparatus, and that is not an apparatus, machine, or apparatus of an article used for the purpose of giving pharmacological effects to the structure or function of a person or animal, It also includes supplies.

When the composition of the present invention is contained in a quasi-drug for the purpose of preventing or ameliorating hair loss or promoting hair growth or hair growth, the composition may be used as it is or may be used in combination with other quasi-drug components, have. The amount of the active ingredient to be mixed can be appropriately determined depending on the purpose of use.

The quasi-drug of the present invention is not particularly limited, but may be used in the form of, for example, a cream, a lotion, an aerosol, a shampoo, an gel or a pack.

In the case of a cream, an ointment, a shampoo, a gel or a pellet, it is preferable to use white petrolatum, yellow petrolatum, lanolin, bleached wax, cetanol, stearyl alcohol, stearic acid, hydrogenated oil, polyethylene glycol, Base of; Solvents and dissolution aids such as oleic acid, myristic acid isopropyl, triisooctanoic acid glycerin, crotamiton, diethyl sebacate, diisopropyl adipate, hexyl laurate, fatty acid, fatty acid ester, aliphatic alcohol and vegetable oil; Antioxidants such as tocopherol derivatives, L-ascorbic acid, dibutylhydroxytoluene, and butylhydroxyanisole; Preservatives such as parahydroxybenzoic acid ester; Humectants such as glycerin, propylene glycol and sodium hyaluronate; Surfactants such as polyoxyethylene derivatives, glycerin fatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, propylene glycol fatty acid esters, and lecithin; Carboxyvinyl polymer, xanthan gum, carboxymethylcellulose, carboxymethylcellulose sodium salt, hydroxypropylcellulose, hydroxypropylmethylcellulose and the like.

In the case of the aerosol preparation, the white petrolatum, the yellow petrolatum, the lanolin, the bleached wax, the cetanol, the stearyl alcohol, the stearic acid, the stearic acid, Base oils such as hydrogenated oils, gelled hydrocarbons, polyethylene glycols, liquid paraffin, squalane and the like; Oleic acid, myristic acid isopropyl, diisopropyl adipate, isobutyl sebacate, glycerin triisooctanoate, crotamiton, diethyl sebacate, hexyl laurate, fatty acid esters, aliphatic alcohols and vegetable oils Solvents and dissolution aids; Antioxidants such as tocopherol derivatives, L-ascorbic acid, dibutylhydroxytoluene, and butylhydroxyanisole; Preservatives such as parahydroxybenzoic acid ester; Humectants such as glycerin, propylene glycol and sodium hyaluronate; Surfactants such as polyoxyethylene derivatives, glycerin fatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, propylene glycol fatty acid esters, and lecithin; Thickening agents such as carboxyvinyl polymer, xanthan gum, carboxymethyl cellulose, carboxymethyl cellulose sodium salts, hydroxypropyl cellulose, hydroxypropylmethyl cellulose and the like; In addition, various stabilizers, buffers, mating agents, suspending agents, emulsifiers, fragrances, preservatives, solubilizers, and other suitable additives may be added.

In addition, a stabilizer, a preservative, an absorption promoter, a pH adjuster, and other suitable additives may be added as necessary.

The present invention also provides a cosmetic composition for preventing or improving hair loss and promoting hair growth or hair growth comprising TYMP protein as an active ingredient.

The cosmetic composition may be at least one selected from the group consisting of a hair tonic, a hair cream, a hair lotion, a hair shampoo, a hair conditioner, a hair conditioner, a hair spray, a hair aerosol, a pomade, a powder gel, a hair pack, a hair treatment, It may, but is not limited to, be a formulation of a nutrient.

In addition, the composition for preventing or improving hair loss, hair growth or hair growth promotion of the present invention may be used for pets in a different form of the composition. For example, a neutral detergent which can be manufactured in various forms such as a solution shampoo for pet and a rinse for pet such as solution, sol gel, emulsion, oil, wax, and aerosol, and is less irritating to pet skin and excellent in moisture And the like.

In addition, the cosmetic composition of the present invention may include, without limitation, commonly accepted ingredients other than the above-mentioned effective ingredients, and includes conventional auxiliary agents such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances, and carriers can do.

In the case of shampoo, it may contain at least one of a synthetic surfactant, which is a cleaning component, and at least one of preservatives, thickeners, viscosity regulators, pH adjusters, perfumes, dyes, hair conditioning agents and water. Examples of the synthetic anionic surfactant in the synthetic surfactant include alkyl and alkyl ether sulfates, and representative examples thereof include sodium lauryl sulfate, ammonium lauryl sulfate, triethanolamine lauryl sulfate, sodium polyoxyethylene lauryl sulfate, polyoxyethylene lauryl sulfate and the like have. The synthetic amphoteric surfactants in the synthetic surfactants are alkyl betamines and alkylamidopropyl betaines. Representative examples include cocodimethyl carboxymethyl betaine, lauryl dimethyl carboxymethyl betaine, lauryl dimethyl alpha-carboxyethyl betaine , Cetyl dimethyl carboxymethyl betaine, and cocamidopropyl betaine. Examples of the nonionic surfactant include alkanolamides and amine oxides such as lauryldiethylamine oxide, palm oil alkyldimethylamine oxide, lauric acid diethanolamide, palm oil fatty acid diethanolamide, palm oil fatty acid monoethanolamide, and the like.

The optional ingredients used in the present invention are well known to those skilled in the art as conventional optional ingredients for maintaining basic properties and quality as a shampoo. Such optional ingredients include, but are not limited to, pearl wood supplements, preservatives, dyes and viscosity modifiers, pH adjusting agents, perfumes, dyes, and hair conditioning agents. Such as ethylene glycol monostearate and ethylene glycol distearate; Preservatives such as methyl paraoxybenzoate, mixtures of methylchloroisothiazolinone and methyl isothiazolinone; Thickeners and viscosity modifiers such as sodium chloride, ammonium chloride, propylene glycol; PH adjusting agents such as citric acid, phosphoric acid, sodium hydroxide and potassium hydroxide; Hair conditioning agents such as polyquaternium-10, polyquaternium-7, methylpolysiloxane, dimethicone copolyols, hydrolyzed animal proteins, dyes such as water-soluble tar, and perfumes can also be used.

The present invention also provides a food composition for preventing or improving hair loss and promoting hair growth or hair growth comprising TYMP protein as an active ingredient.

The food composition of the present invention may be in the form of a health functional food, and the "health functional food" may be a food prepared or processed by using a raw material or ingredient having a useful function in the human body according to the Health Functional Food No. 6727 , And "functional" means that the structure and function of the human body is ingested for the purpose of obtaining nutritional control, physiological action, and other effects useful for health use.

The above food composition may further include food additives, and the suitability of the food additives as "food additives" is to be determined by the Food and Drug Administration in accordance with the general provisions of the Food Additives Ordinance approved by the Food and Drug Administration, Judge by standards.

Examples of the products listed in the above-mentioned "food additives" include natural products such as ketones, chemical products such as glycine, potassium citrate, nicotinic acid and cinnamic acid, coloring matter, licorice extract, crystalline cellulose, guar gum, Sodium laurate, sodium glutamate preparation, noodles-added alkaline agent, preservative agent, tar pigment preparation and the like.

Examples of foods containing the active ingredient of the present invention include confectionery ice creams such as bread, rice cake, dried fruits, candy, chocolate, chewing gum and mackerel, ice cream products such as ice cream, ice cream powder, low-fat milk, Dairy products such as processed oil, goat milk, fermented oil, butter oil, concentrated oil, yogurt cream, butter oil, natural cheese, processed cheese, milk powder, milk products, meat products such as hamburger, ham, Fish oil products such as sausage, bacon, etc. Fish products such as instant noodles, dried noodles, fresh noodles, noodle noodles, luxury dried noodles, improved sleep noodles, frozen noodles, noodles such as pasta, vegetable drinks, Seasonings such as bean paste, soybean paste, red pepper paste, chukjang, chonggukjang, mixed berries, vinegar, sauce, tomato ketchup, curry, dressing, margarine, But are the teuning and pizza, without being limited thereto.

In addition to the above, the composition of the present invention may further contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, A carbonating agent used in a carbonated beverage, and the like. In addition, the composition of the present invention may comprise flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. Although the ratio of such additives is not critical, it is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

The beverage composition containing the active ingredient of the present invention is not particularly limited to the other ingredients other than those containing the protein, and may contain various flavors or natural carbohydrates such as ordinary beverages as an additional ingredient. Examples of the above-mentioned natural carbohydrates include monosaccharides (e.g., glucose, fructose, etc.); Disaccharide, (e.g., maltose, sucrose, etc.); And polysaccharides (for example, dextrin, cyclodextrin and the like), and sugar alcohols such as xylitol, sorbitol and erythritol. As natural flavors other than those described above, natural flavors (such as tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin)) and synthetic flavors (saccharin, aspartame, etc.) have.

The present invention will be described in more detail with reference to Examples and Experimental Examples. However, the following examples and experimental examples are provided to illustrate the present invention in a more easily understandable manner, and the content of the present invention is not limited by the examples. In this case, , And has a general meaning to those having ordinary skill in the art to which this invention belongs.

Example  One. TYMP's  purchase

TYMP (thymidine phosphorylase) protein was purchased from Peprotech. The amino acid sequence and DNA base sequence of the obtained TYMP protein were analyzed and confirmed, and the results are shown in SEQ ID NOS: 1 and 2.

Example  2. TYMP's  Confirm cell proliferation effect

Human dermal papilla cell (DPC) proliferation experiments were performed, which is a representative in vitro cell lysing system for measuring hair growth potential. 1 or 5 ng / ml of the TYMP protein of Example 1 was treated with DPC and the proliferation was measured for 40 hours. The results are shown in Fig.

As shown in Fig. 1, when the TYMP protein was treated with DPC, it was confirmed that the cell proliferation was increased more than the TYMP protein-untreated cell.

From the above results, it was confirmed that the TYMP protein has an excellent cell proliferation effect and thus can be utilized for hair loss treatment or hair growth promotion.

Example  3. TYMP's  Verification of hair growth effect

For the experiment to confirm the hair growth effect, hair of C3H / HeN mouse at 7 weeks of age was removed with hair removal agent and stabilized. After one day, 100 ng / ml of human TYMP (thymidine phosphorylase) (SEQ. ID. NO: 1) protein was subcutaneously injected once into the back. As a control, PBS (phosphate buffered saline) containing the same volume of 0.1% BSA in which the TYMP protein was dissolved was subcutaneously injected. Thereafter, the degree of hair growth of the dorsal part of the depilated mouse was observed for 15 days. FIG. 2 shows a photograph of a back part of a mouse with hair growth.

As shown in FIG. 2, it was confirmed that the hairy condition was more excellent in the TYMP protein-treated group than in the control group.

In addition, after 15 days, hair was removed from a back part of a mouse having a new hair growth using a knife, and the weight of the obtained hair was measured. The result is shown in FIG.

As shown in FIG. 3, the measured hair growth weight was 40 mg in the control group, whereas it was 90 mg in the TYMP protein-treated group. Thus, it was confirmed that the treatment with TYMP protein was excellent in the hair growth promoting effect .

From the above results, it was confirmed that the TYMP protein component had an excellent hair growth effect and could be used as a composition for prevention and treatment of hair loss.

Hereinafter, the pharmaceutical compositions for preventing or treating hair loss, the cosmetic compositions for preventing and alleviating hair loss, and the pharmaceutical compositions containing the active ingredients of the present invention will be described, but the present invention is not limited thereto .

Formulation example  1. Preparation of pharmaceutical preparations

1. Manufacturing of powder

TYMP protein 20 mg

Lactose 100 mg

Talc 10 mg

The above components are mixed and filled in airtight bags to prepare powders.

2. Preparation of tablets

TYMP protein 10 mg

Corn starch 100 mg

Lactose 100 mg

Magnesium stearate 2 mg

After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.

3. Preparation of capsules

TYMP protein 10 mg

Crystalline cellulose 3 mg

Lactose 14.8 mg

Magnesium stearate 0.2 mg

The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.

4. Preparation of injections

TYMP protein 10 mg

180 mg mannitol

Sterile sterilized water for injection 2974 mg

Na ₂ HPO ₄ 2H ₂ O 26 mg

(2 ml) per 1 ampoule in accordance with the usual injection preparation method.

5. Manufacture of liquids

TYMP protein 20 mg

10 g per isomer

5 g mannitol

Purified water quantity

Each component was added and dissolved in purified water according to the usual liquid preparation method, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was added with purified water to adjust the total volume to 100 ml, And sterilized to prepare a liquid preparation.

Formulation example  2. Manufacture of cosmetic preparations

1. Hair lotion manufacturing

0.6% by weight of TYMP protein

Glycerin 5.1 wt%

Propylene glycol 4.2 wt%

3.0% by weight of tocopheryl acetate

Liquid paraffin 4.6 wt%

1.0% by weight triethanolamine

Squalane 3.1 wt%

Macadamia nut oil 2.5 wt%

Polysorbate 60 1.6 wt%

1.6% by weight of sorbitan sesquiterate

Propyl paraben 0.6 wt%

Carboxyl vinyl polymer 1.5 wt%

Fragrance

Antiseptic

Purified water balance

2. Hair cream production

1.0% by weight of TYMP protein

Glycerin 4.0 wt%

Vaseline 3.5 wt%

2.1% by weight triethanolamine

Liquid paraffin 53 wt%

Squalane 3.0 wt%

Wax 2.6 wt%

Tocopheryl acetate 5.4 wt%

Polysorbate 60 3.2 wt%

Carboxyl vinyl polymer 1.0 wt%

3.1 weight percent sorbitan sesquioleate

Fragrance

Antiseptic

Purified water balance

3. Hair shampoo manufacturing

TYMP protein 5.8 wt%

35% by weight sodium laureth < RTI ID = 0.0 >

1% by weight of glycerin

3.5% by weight < RTI ID = 0.0 >

1% by weight of propylene glycol

Cocoamidopropyl betaine 1 wt%

Cetyl alcohol 0.1 wt%

0.5% by weight of glycol distearate

8% by weight of butylene glycol

0.2% by weight of methylparaben

0.1% by weight triethanolamine

Citric acid 0.1 wt%

Polyquaternium-7 0.2 wt%

Polycatanium-10 0.12 wt%

Olive oil < SEP > Fiji-7 &

Fragrance

Antiseptic

Purified water balance

Formulation example  3. Manufacture of food preparation

1. Manufacture of health food

100 mg of TYMP protein

Vitamin mixture quantity

70 g of vitamin A acetate

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

0.15 mg of vitamin B2

Vitamin B6 0.5 mg

0.2 g of vitamin B12

Vitamin C 10 mg

Biotin 10 g

Nicotinic acid amide 1.7 mg

Folate 50 g

Calcium pantothenate 0.5 mg

Mineral mixture quantity

1.75 mg of ferrous sulfate

0.82 mg of zinc oxide

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Secondary calcium phosphate 55 mg

Potassium citrate 90 mg

Calcium carbonate 100 mg

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

2. Manufacture of health drinks

100 mg of TYMP protein

Vitamin C 15 g

Vitamin E (powder) 100 g

19.75 g of ferrous lactate

3.5 g of zinc oxide

Nicotinic acid amide 3.5 g

Vitamin A 0.2 g

Vitamin B1 0.25 g

Vitamin B2 0.3 g

Water quantification

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 DEG C for about 1 hour. The resulting solution was filtered and sterilized in a sterilized 2 L container, ≪ / RTI >

Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.

<110> SCM Lifescience Co., Ltd <120> Pharmaceutical composition for preventing or treating hair loss          comprising TYMP (thymidine phosphorylase) protein <130> 1-3P <160> 2 <170> Kopatentin 2.0 <210> 1 <211> 482 <212> PRT <213> Homo sapiens <400> 1 Met Ala Leu Met Thr Pro Gly Thr Gly Ala Pro Pro Ala Pro Gly   1 5 10 15 Asp Phe Ser Gly Glu Gly Ser Gln Gly Leu Pro Asp Pro Ser Pro Glu              20 25 30 Pro Lys Gln Leu Pro Glu Leu Ile Arg Met Lys Arg Asp Gly Gly Arg          35 40 45 Leu Ser Glu Ala Asp Ile Arg Gly Phe Val Ala Val Val Asn Gly      50 55 60 Ser Ala Gln Gly Ala Gln Ile Gly Ala Met Leu Met Ala Ile Arg Leu  65 70 75 80 Arg Gly Met Asp Leu Glu Glu Thr Ser Val Leu Thr Gln Ala Leu Ala                  85 90 95 Gln Ser Gly Gln Gln Leu Glu Trp Pro Glu Ala Trp Arg Gln Gln Leu             100 105 110 Val Asp Lys His Ser Thr Gly Gly Val Gly Asp Lys Val Ser Leu Val         115 120 125 Leu Ala Pro Ala Leu Ala Ala Cys Gly Cys Lys Val Pro Met Ile Ser     130 135 140 Gly Arg Gly Leu Gly His Thr Gly Gly Thr Leu Asp Lys Leu Glu Ser 145 150 155 160 Ile Pro Gly Phe Asn Val Ile Gln Ser Pro Glu Gln Met Gln Val Leu                 165 170 175 Leu Asp Gln Ala Gly Cys Cys Ile Val Gly Gln Ser Glu Gln Leu Val             180 185 190 Pro Ala Asp Gly Ile Leu Tyr Ala Ala Arg Asp Val Thr Ala Thr Val         195 200 205 Asp Ser Leu Pro Leu Ile Thr Ala Ser Ile Leu Ser Lys Lys Leu Val     210 215 220 Glu Gly Leu Ser Ala Leu Val Val Asp Val Lys Phe Gly Gly Ala Ala 225 230 235 240 Val Phe Pro Asn Gln Glu Gln Ala Arg Glu Leu Ala Lys Thr Leu Val                 245 250 255 Gly Val Gly Ala Ala Leu Thr Ala             260 265 270 Met Asp Lys Pro Leu Gly Arg Cys Val Gly His Ala Leu Glu Val Glu         275 280 285 Glu Ala Leu Leu Cys Met Asp Gly Ala Gly Pro Pro Asp Leu Arg Asp     290 295 300 Leu Val Thr Thr Leu Gly Gly Ala Leu Leu Trp Leu Ser Gly His Ala 305 310 315 320 Gly Thr Gln Ala Gln Gly Ala Ala Arg Val Ala Ala Ala Leu Asp Asp                 325 330 335 Gly Ser Ala Leu Gly Arg Phe Glu Arg Met Leu Ala Ala Gln Gly Val             340 345 350 Asp Pro Gly Leu Ala Arg Ala Leu Cys Ser Gly Ser Pro Ala Glu Arg         355 360 365 Arg Gln Leu Leu Pro Arg Ala Arg Glu Gln Glu Glu Leu Leu Ala Pro     370 375 380 Ala Asp Gly Thr Val Gul Leu Val Arg Ala Leu Pro Leu Ala Leu Val 385 390 395 400 Leu His Glu Leu Gly Ala Gly Arg Ser Ser Ala Gly Glu Pro Leu Arg                 405 410 415 Leu Gly Val Gly Ala Glu Leu Leu Val Asp Val Gly Gln Arg Leu Arg             420 425 430 Arg Gly Thr Pro Trp Leu Arg Val His Arg Asp Gly Pro Ala Leu Ser         435 440 445 Gly Pro Gln Ser Arg Ala Leu Gln Glu Ala Leu Val Leu Ser Asp Arg     450 455 460 Ala Pro Phe Ala Ala Pro Ser Pro Phe Ala Glu Leu Val Leu Pro Pro 465 470 475 480 Gln Gln         <210> 2 <211> 1449 <212> DNA <213> Homo sapiens <400> 2 atggcagcct tgatgacccc gggaaccggg gccccacccg cgcctggtga cttctccggg 60 gaagggagcc agggacttcc cgacccttcg ccagagccca agcagctccc ggagctgatc 120 cgcatgaagc gagacggagg ccgcctgagc gaagcggaca tcaggggctt cgtggccgct 180 gtggtgaatg ggagcgcgca gggcgcacag atcggggcca tgctgatggc catccgactt 240 cggggcatgg atctggagga gacctcggtg ctgacccagg ccctggctca gtcgggacag 300 cagctggagt ggccagaggc ctggcgccag cagcttgtgg acaagcattc cacagggggt 360 gtgggtgaca aggtcagcct ggtcctcgca cctgccctgg cggcatgtgg ctgcaaggtg 420 ccaatgatca gcggacgtgg tctggggcac acaggaggca ccttggataa gctggagtct 480 attcctggat tcaatgtcat ccagagccca gagcagatgc aagtgctgct ggaccaggcg 540 ggctgctgta tcgtgggtca gagtgagcag ctggttcctg cggacggaat cctatatgca 600 gccagagatg tgacagccac cgtggacagc ctgccactca tcacagcctc cattctcagt 660 aagaaactcg tggaggggct gtccgctctg gtggtggacg ttaagttcgg aggggccgcc 720 gtcttcccca accaggagca ggcccgggag ctggcaaaga cgctggttgg cgtgggagcc 780 agcctagggc ttcgggtcgc ggcagcgctg accgccatgg acaagcccct gggtcgctgc 840 gtgggccacg ccctggaggt ggaggaggcg ctgctctgca tggacggcgc aggcccgcca 900 gacttaaggg acctggtcac cacgctcggg ggcgccctgc tctggctcag cggacacgcg 960 gggactcagg cccagggcgc tgcccgggtg gccgcggcgc tggacgacgg ctcggccctt 1020 ggccgcttcg agcggatgct ggcggcgcag ggcgtggatc ccggtctggc ccgagccctg 1080 tgctcgggaa gtcccgcaga acgccggcag ctgctgcctc gcgcccggga gcaggaggag 1140 ctgctggcgc ccgcagatgg caccgtggag ctggtccggg cgctgccgct ggcgctggtg 1200 ctgcacgagc tcggggccgg gcgcagccgc gctggggagc cgctccgcct gggggtgggc 1260 gcagagctgc tggtcgacgt gggtcagagg ctgcgccgtg ggaccccctg gctccgcgtg 1320 caccgggacg gccccgcgct cagcggcccg cagagccgcg ccctgcagga ggcgctcgta 1380 ctctccgacc gcgcgccatt cgccgccccc tcgcccttcg cagagctcgt tctgccgccg 1440 cagcaataa 1449

Claims (13)

A pharmaceutical composition for prevention or treatment of hair loss comprising TYMP (thymidine phosphorylase) protein as an active ingredient.
The method according to claim 1,
Wherein the TYMP protein is composed of the amino acid sequence of SEQ ID NO: 1.
The method according to claim 1,
Wherein the TYMP protein is encoded by the polynucleotide of SEQ ID NO: 2.
The method according to claim 1,
Wherein said hair loss is at least one selected from the group consisting of male pattern hair loss, female pattern hair loss, circular hair loss, and resting hair loss.
A quasi-composition for prevention or improvement of hair loss comprising TYMP protein as an active ingredient.
6. The method of claim 5,
Wherein the quasi-drug has at least one formulation selected from the group consisting of cream, lotion, aerosol, shampoo, gel, and pack.
A cosmetic composition for prevention or improvement of hair loss comprising TYMP protein as an active ingredient.
The cosmetic composition according to claim 7, wherein the cosmetic composition is at least one selected from the group consisting of hair tonic, hair cream, hair lotion, hair shampoo, hair conditioner, hair conditioner, hair spray, hair aerosol, pomade, powder gel, hair pack, hair treatment, And an eyelash nutrient, wherein the composition is at least one of the following:
A food composition for prevention or alleviation of hair loss comprising TYMP protein as an active ingredient.
A pharmaceutical composition for promoting hair growth or hair growth comprising TYMP protein as an active ingredient.
A quasi-drug composition for promoting hair growth or hair growth comprising TYMP protein as an active ingredient.
A cosmetic composition for promoting hair growth or hair growth comprising TYMP protein as an active ingredient.
A food composition for promoting hair growth or hair growth comprising TYMP protein as an active ingredient.

Images